NICE announces details of health technology evaluation methods review
Following approval at its recent Board meeting NICE has confirmed the details of its review of the methods it uses to develop guidance on drugs, medical devices and diagnostics.
Latest news headlines
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in draft guidance published today (17 July 2019).
17 July 2019
It’s estimated that around 90,000 people could be eligible for treatment with dapagliflozin
12 July 2019
People presenting erythema migrans, the characteristic skin rash associated with Lyme disease, can be diagnosed and treated without the need for blood tests, NICE has said in a final quality standard published today.
10 July 2019
The National Institute for Health and Care Excellence (NICE), in collaboration with several other partner organisations, has launched a new initiative to encourage better medicines support for people who are receiving social care services in their homes.
09 July 2019
A handheld device that delivers a small electric current has been recommended by NICE for the prevention and treatment of cluster headaches, a rare but painful type of headache that affects around 100,000 people in the UK.
05 July 2019
Dacomitinib has been recommended as a first-line treatment option for people with a type of non-small-cell lung cancer (NSCLC), in new NICE guidance.
05 July 2019